{"name":"BenevolentAI","slug":"benevolent","ticker":"BAI","exchange":"Euronext Amsterdam","domain":"benevolent.com","description":"BenevolentAI is a UK-based artificial intelligence (AI) company focused on drug discovery. The company uses its AI platform to identify potential new treatments for various diseases. BenevolentAI has a pipeline of several drugs in various stages of development. The company is positioning itself as a leader in the AI-driven drug discovery space.","hq":"London, United Kingdom","founded":0,"employees":"","ceo":"Joerg Moeller","sector":"AI Drug Discovery","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$220M","metrics":{"revenue":45000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BEN-2001","genericName":"BEN-2001","slug":"ben-2001","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"BEN-2001","genericName":"BEN-2001","slug":"ben-2001","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-08-23","type":"deal","headline":"BenevolentAI raises $100m in funding","summary":"BenevolentAI has secured $100m in funding to support its AI-driven drug discovery efforts.","drugName":"","sentiment":"positive"},{"date":"2024-06-20","type":"regulatory","headline":"BenevolentAI's lead candidate receives orphan drug designation","summary":"BenevolentAI's lead candidate has received orphan drug designation from the FDA, providing potential market exclusivity.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPNkVNME96MHdJN2hFajNPZ09hQmNTcjUxZXRVSi1CdllpdDliRkF6eUEyMVN0MjJEY3RXYkE0R0tSR1F3SDBTYi1YRndTMTZpWFNpajBFcjc4MHRCV3EtbHNXU0Y2VWZCZF9xdkV2SmZ1WHFhY21uMElFUWNpY2dsUEk4UV9kanUzbTZDWDFobjhSNUdtT2RyT0tLSkIzVXloLVZIendR?oc=5","date":"2024-12-20","type":"pipeline","source":"The Pharma Letter","summary":"Major overhaul at BenevolentAI includes possible delisting - The Pharma Letter","headline":"Major overhaul at BenevolentAI includes possible delisting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOOUc5R1NFYlJ5cENPZXNVQnNiaTFoeEVWd28yUDdwY2l5alJmRkZndjVsSHZfR1FHYmVYMmUwYkVPQkUyZmV5bExsUmJHVW94LXBvSTJCdHl3UFJnN3BwSVdCZXhqTjBnWlpKaUtlSDNwaUZDU0ZiRjRmMmZxSi0yQ3VCb3B6ZkFSTUFvVE1XNjZENVJGYW5leVFibUFEazhiQW5LRFFQd29rV0Q2bHduZFk1akY5aHhfbkNsRHdKSUw2SWV0bGhMUkdNLV84bFU?oc=5","date":"2024-12-11","type":"pipeline","source":"Business Wire","summary":"BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission - Business Wire","headline":"BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPc2RaTG5qOEVYU1JtS29yWEpybXpxbGEtVkJOTGhiNGNhcTlUNHBsd0xvdGhEcmkyd0l0NDBLLTNESW56QktfUmU4dGM0MkJJT3c5RlpZZmRSZFlYMm9HYjE4UllzM29IeEhlMU9vVk14OFJzSDJqU3hkWUtabGZDUnM4ZUxnWjRJaHR1RGw4Nm1UX2c?oc=5","date":"2024-12-11","type":"pipeline","source":"MedCity News","summary":"AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots - MedCity News","headline":"AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOT3BKV05xanFYV1lCelpkdHU2V2pVMUVPMTBHVGtkV0g3VktCWUJYazNEaFcwczg4UkVhekNFQVdicnd0VXNnMzBKUTEzb1c3QjNaLWUtbWc2N3pmVVZWU1pMOURJaGlBa0c0QlphcWlab2ZaV1BSTzNwU0dpODM3SW1ZZlc1MjRaYnRMaGJPVDNsakNFcEpzdFBJbXFsM3ZiZGE0OHlfb0poZFJFcHVscmxRQnMwc0t6QTln?oc=5","date":"2024-10-18","type":"pipeline","source":"The Pharma Letter","summary":"BenevolentAI founder returns as executive chairman amid leadership overhaul - The Pharma Letter","headline":"BenevolentAI founder returns as executive chairman amid leadership overhaul","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQWFBxdWh4VUlXOUl3SXZnSHNneFY1R3htYjdIU0tod04tZHRVUVh1MllldFJINkFXY2FqZWh4NHN3UURyZjVPdVB3bU9CUE5VRnRIX3lxWXVGN0hQdmlJaWFkNFNoUVVQLUlKS0FVWkt4Tmk2bFlhZmtuSmNUalhYc2JPQUstczNyNDQ3M2NR?oc=5","date":"2024-05-30","type":"pipeline","source":"Yahoo Finance","summary":"BenevolentAI S.A. (AMS:BAI) Is Expected To Breakeven In The Near Future - Yahoo Finance","headline":"BenevolentAI S.A. (AMS:BAI) Is Expected To Breakeven In The Near Future","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOcXNCRzR2bnZ1NkVsdF9UeUZ4UkZrU2h3dWppVFphRllvT3dDNUhjbFpzR2psOTZVM1JrSjI1ZThLeFhLUVF5MXl4YVhoU3FyYU94Q1otMVh6S2FnVlExRVRkSlNpT2JoV1R1WU5yN3NKaUdJQm9GUmtsYUVOUVlSQkN6Um9ES1g5bUE?oc=5","date":"2024-04-11","type":"pipeline","source":"thebambooworks.com","summary":"InSilico seeks IPO boost to get AI drugs over the line - thebambooworks.com","headline":"InSilico seeks IPO boost to get AI drugs over the line","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE11YmVETW1jMlBjaElVa2ZaY1ljbUhodEp2YW9OOFB6V2ZMR0JjalMzaGZXbmI3WDlydXJhc04ySG04MHlLT1V1RVF2RjV0Y19PazVqNjBXUndXNjdvcE5ydV8yVXFSUnB0b3hWRGNoNW5MUQ?oc=5","date":"2023-06-30","type":"pipeline","source":"Nanalyze","summary":"A Review of Seven AI Drug Discovery Stocks - Nanalyze","headline":"A Review of Seven AI Drug Discovery Stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNTXhsUmpNOWNJbnpOQXN4RXJkZDVpTy01X1doQU1GcGhMYjMtSXp6RExSMEcza01zT3pBdUJlb2tLLW1FSU4yakVEYWtJRnAxcFNvZ0RxZDZjandCX1J4dTJ5RkQ0RUVHUVJ5ZmlrYm84T0FJclpET1FUMGJrU2hMR2p1UlB6VFZlMUtEaV85N1IwNEx3aTFHak52Q24?oc=5","date":"2023-05-03","type":"pipeline","source":"drugdiscoverytrends.com","summary":"BenevolentAI exploring novel AI-driven drug discovery methods - drugdiscoverytrends.com","headline":"BenevolentAI exploring novel AI-driven drug discovery methods","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["DeepMind","Insilico Medicine","Recursion Pharmaceuticals"],"therapeuticFocus":["Oncology","Neurology"],"financials":null,"yahoo":null}